ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0554

Association of Total Kidney Volume and Diabetes with CKD Progression and Mortality Outcomes in ADPKD

Session Information

Category: Genetic Diseases of the Kidneys

  • 1201 Genetic Diseases of the Kidneys: Monogenic Kidney Diseases

Authors

  • Robinson-Cohen, Cassianne, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Battram, Thomas, Bayer AG, Leverkusen, NRW, Germany
  • Below, Jennifer E., Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Kota, Savithri B., Bayer AG, Leverkusen, NRW, Germany
  • Hung, Adriana, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Petty, Alexander S, Vanderbilt University Medical Center, Nashville, Tennessee, United States
Background

Autosomal dominant polycystic kidney disease (ADPKD) is a heritable disorder marked by cystic kidney enlargement, progressive kidney function decline, and high risk of end-stage kidney disease (ESKD). Diabetes is a common comorbidity that may influence disease progression, though its role remains uncertain.

Methods

We conducted a cohort study of adults with ADPKD treated at Vanderbilt University Medical Center (1996–2024), defining baseline as the first available TKV measurement (MRI or ultrasound). Outcomes included incident CKD progression (50% eGFR decline or kidney failure) and death. Cox models assessed associations between TKV and outcomes, overall and by diabetes status.

Results

Among 1,317 participants (mean age 57±15 years, 43% female), 35% had diabetes. Median baseline TKV was 518 mL (IQR 489–596). Over a median 3.2 years, 305 developed CKD progression and 354 died. Each doubling in TKV was associated with higher mortality (HR 1.28 [1.05–1.56]) but not with CKD progression (HR 0.95 [0.55–1.64]). In non-diabetic patients, higher TKV was associated with both death (HR 1.43 [0.94–2.18]) and CKD progression (HR 1.67 [1.08–2.58]). No significant associations were seen among those with diabetes.

Conclusion

Larger TKV was linked to increased mortality in ADPKD, especially among non-diabetics. Diabetes may alter the typical structural-functional trajectory in ADPKD, underscoring the need to account for comorbidity profiles when evaluating TKV as a prognostic marker.

Funding

  • Commercial Support – Bayer

Digital Object Identifier (DOI)